LUCD Valuation

Lucid Diagnostics Inc

Add to Watchlist

Advanced Chart

1.285

-0.005(-0.390%)

Overview
Forecast
Valuation

LUCD Relative Valuation

LUCD's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, LUCD is overvalued; if below, it's undervalued.

Historical Valuation

Lucid Diagnostics Inc (LUCD) is now in the Overvalued zone, suggesting that its current forward PS ratio of 15.57 is considered Overvalued compared with the five-year average of 28.00. The fair price of Lucid Diagnostics Inc (LUCD) is between 0.47 to 0.81 according to relative valuation methord. Compared to the current price of 1.28 USD , Lucid Diagnostics Inc is Overvalued By 58.70%.

Relative Value

Fair Zone

0.47-0.81

Current Price：1.28

58.70%

Overvalued

Trailing

Forward

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

-1.65

P/B

Median3y

3.65

Median5y

3.01

-33.42

FCF Yield

Median3y

-60.47

Median5y

-52.79

Competitors Valuation Multiple

The average P/S ratio for LUCD's competitors is 4.40, providing a benchmark for relative valuation. Lucid Diagnostics Inc Corp (LUCD) exhibits a P/S ratio of 15.57, which is 254.25% above the industry average. Given its robust revenue growth of 15.10%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

LUCD.O

Lucid Diagnostics Inc

15.57

Average P/S: 4.40

15.10%